Diabetes Management
Lixisenatide—Once-daily Glucagon-like Peptide-1 Receptor Agonist in the Management of Type 2 Diabetes
Celeste C L Quianzon, MD1 and Mansur E Shomali, MD, CM2
1. Senior Fellow in Endocrinology, Diabetes and Metabolism; 2. Program Director, Endocrinology, Diabetes and Metabolism Training Program, Division of Endocrinology, Diabetes and Metabolism, Department of Medicine, Union Memorial Hospital
Abstract The glucagon-like peptide-1 receptor agonist diabetes medications have become important due to their unique features, such as their potency
of glycosylated hemoglobin (HbA1C) lowering, durability of effect, glucose-depending insulin secretion resulting in a low risk of hypoglycemia, glucagon suppression, and weight loss. Lixisenatide is an investigational compound in this class, exhibits all of these features, and has some unique properties, which are highlighted in this review. The pharmacology of lixisenatide, the results of recent clinical trials investigating this agent, and its potential role in the management of type 2 diabetes will be discussed.
Keywords Lixisenatide, glucagon-like peptide-1 receptor agonist, type 2 diabetes
Disclosure: The authors have no conflicts of interest to declare. Received: August 8, 2011 Accepted: October 3, 2011 Citation: US Endocrinology, 2011;7(2):104–9 Correspondence: Mansur E Shomali, MD, CM, Division of Endocrinology, Diabetes and Metabolism, Union Memorial Hospital, 201 E. University Parkway, Baltimore, MD 21218. E:
mansur.shomali@
medstar.net
Type 2 diabetes is a progressive disease of the beta cells characterized by declining insulin secretion and varying degrees of insulin resistance resulting in hyperglycemia. It is a chronic progressive disease of increasing incidence. In the USA, 25.6 million people aged over 20 years have type 2 diabetes1
36 million people in the next 20 years.2
and the prevalence is projected to increase to This trend follows that of the
obesity epidemic. Patients with type 2 diabetes are at increased risk of microvascular and macrovascular complications (neuropathy, renal disease, retinopathy, myocardial infarction, cerebrovascular accident, peripheral vascular disease). Most patients need lifestyle changes and polypharmacy to control hyperglycemia.
The American Association of Clinical Endocrinologists and American Diabetes Association guidelines recommend lifestyle changes and metformin as first-line therapy.3,4
The glucagon-like peptide-1 (GLP-1)
receptor agonist class of medications may be used, typically as part of combination therapy, and may have certain advantages over older medications. GLP-1 receptor agonists stimulate insulin secretion in a glucose-dependent manner (thus having a low risk of hypoglycemia), suppress glucagon secretion, improve beta cell function, slow down gastric emptying, and promote early satiety and consequent weight loss.5,6 In addition, GLP-1 agonists have potential cardiovascular benefits with weight reduction, improvements in lipid profile and blood pressure, and decreased markers for cardiovascular risk and inflammation (including C-reactive protein).7
GLP-1 receptor agonists approved by the US Food and Drug Administration are twice-daily exenatide (Byetta®; Amylin 104
Pharmaceuticals, Inc. and Lilly USA, LLC) and once-daily liraglutide (Victoza®; Novo Nordisk). This article reviews lixisenatide (Lyxumia®, AVE0010, ZP10), an investigational once-daily GLP-1 receptor agonist in phase III development for the treatment of type 2 diabetes, which is being developed by Sanofi-aventis under license from Zealand Pharma A/S.8
Pharmacology
Lixisenatide is a 44-amino-acid peptide based on exendin-49 and modified to avoid rapid degradation by dipeptidyl peptidase-IV.10 The modification consists of the deletion of one proline residue and addition of six lysine residues at the C-terminal.11
exendin-4 for the GLP-1 receptor is similar to that of human GLP-1,9
While the affinity of the
affinity of lixisenatide for the GLP-1 receptor is four times greater than that of human GLP-19,12
highly selective for the GLP-1 receptor.13
(see Figure 1 and Table 1). Lixisenatide is also Pharmacokinetics studies show
that maximum lixisenatide plasma concentration (Cmax) of 84 pg/ml is seen two hours (tmax) after the subcutaneous injection of lixisenatide 20 µg.14
The half-life (t½) is 2.6 ± 1 hours.15 glomerulus and degraded in the renal tubules.15
parameters for lixisenatide and the other GLP-1 receptor agonists are shown in Table 1.
Preclinical Studies
In a study using rat insulinoma cell line INS-1, lixisenatide protected B-cells against fatty acid and cytokine-induced apoptosis9,16 inhibition of cytokine-induced apoptosis was significantly greater with
and © TOUCH BRIEFINGS 2011
Lixisenatide is filtered in the Pharmacokinetic
Page 1 |
Page 2 |
Page 3 |
Page 4 |
Page 5 |
Page 6 |
Page 7 |
Page 8 |
Page 9 |
Page 10 |
Page 11 |
Page 12 |
Page 13 |
Page 14 |
Page 15 |
Page 16 |
Page 17 |
Page 18 |
Page 19 |
Page 20 |
Page 21 |
Page 22 |
Page 23 |
Page 24 |
Page 25 |
Page 26 |
Page 27 |
Page 28 |
Page 29 |
Page 30 |
Page 31 |
Page 32 |
Page 33 |
Page 34 |
Page 35 |
Page 36 |
Page 37 |
Page 38 |
Page 39 |
Page 40 |
Page 41 |
Page 42 |
Page 43 |
Page 44 |
Page 45 |
Page 46 |
Page 47 |
Page 48 |
Page 49 |
Page 50 |
Page 51 |
Page 52 |
Page 53 |
Page 54 |
Page 55 |
Page 56 |
Page 57 |
Page 58 |
Page 59 |
Page 60 |
Page 61 |
Page 62 |
Page 63 |
Page 64 |
Page 65 |
Page 66 |
Page 67 |
Page 68 |
Page 69 |
Page 70 |
Page 71 |
Page 72 |
Page 73 |
Page 74 |
Page 75 |
Page 76 |
Page 77 |
Page 78 |
Page 79 |
Page 80 |
Page 81 |
Page 82 |
Page 83 |
Page 84